000298230 001__ 298230
000298230 005__ 20250518020535.0
000298230 0247_ $$2doi$$a10.1002/ijc.35348
000298230 0247_ $$2pmid$$apmid:39865612
000298230 0247_ $$2ISSN$$a0020-7136
000298230 0247_ $$2ISSN$$a1097-0215
000298230 0247_ $$2altmetric$$aaltmetric:173818450
000298230 037__ $$aDKFZ-2025-00237
000298230 041__ $$aEnglish
000298230 082__ $$a610
000298230 1001_ $$00000-0002-2731-8532$$aLöfling, Leif Lukas$$b0
000298230 245__ $$aBeta-blockers and epithelial ovarian cancer survival: A Norwegian population-based cohort study.
000298230 260__ $$aBognor Regis$$bWiley-Liss$$c2025
000298230 3367_ $$2DRIVER$$aarticle
000298230 3367_ $$2DataCite$$aOutput Types/Journal article
000298230 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1747037513_28858
000298230 3367_ $$2BibTeX$$aARTICLE
000298230 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000298230 3367_ $$00$$2EndNote$$aJournal Article
000298230 500__ $$a2025 Jul 1;157(1):86-94
000298230 520__ $$aCancer diagnosis and therapy cause stress to the body. Preclinical studies have shown that stress hormones can stimulate tumor progression and metastasis by interacting with β-adrenergic receptors, and that β-blockers can inhibit those processes. We assessed if β-blocker use was associated with survival in a nationwide cohort of women with epithelial ovarian cancer (EOC). We identified all women aged ≥40 years who underwent EOC surgery in 2004-2018 in Norway through the Cancer Registry of Norway. We estimated the association between peri-diagnostic and post-diagnostic β-blocker use and survival. We used Cox models, adjusted for sociodemographic and health factors, and reported hazard ratios (HRs) and 95% confidence intervals (CIs). The difference in overall survival time between β-blocker users and non-users was estimated as the difference in restricted mean survival time at 5 years after diagnosis using flexible parametric models. We included 3911 women with EOC; 540 (14%) used β-blockers at diagnosis, 1672 (43%) died of the disease, and 1882 (48%) died overall. We found an association between peri-diagnostic β-blocker use and longer EOC-specific survival (HR = 0.85, 95%CI 0.73-1.00; p-value = 0.048), and an indication of an association with overall survival (HR = 0.89, 95%CI 0.77-1.02; p-value = 0.101). Analysis of post-diagnostic β-blocker use, which included only women who survived 12 months or longer (n = 3344), found similar associations. At 5 years from diagnosis, peri-diagnostic β-blocker users lived on average 1.28 months longer than non-users (95%CI 0.01-2.60 months). The results support the hypothesis that β-blocker use improves EOC-specific survival in women with EOC.
000298230 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000298230 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000298230 650_7 $$2Other$$abeta‐blockers
000298230 650_7 $$2Other$$aovarian cancer
000298230 650_7 $$2Other$$apopulation‐based
000298230 650_7 $$2Other$$aregistry
000298230 650_7 $$2Other$$asurvival
000298230 7001_ $$aStøer, Nathalie C$$b1
000298230 7001_ $$aSloan, Erica K$$b2
000298230 7001_ $$00000-0003-3142-0596$$aNafisi, Sara$$b3
000298230 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aFortner, Renée Turzanski$$b4$$udkfz
000298230 7001_ $$00000-0002-9023-8068$$aBotteri, Edoardo$$b5
000298230 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.35348$$gp. ijc.35348$$n1$$p86-94$$tInternational journal of cancer$$v157$$x0020-7136$$y2025
000298230 909CO $$ooai:inrepo02.dkfz.de:298230$$pVDB
000298230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000298230 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000298230 9141_ $$y2025
000298230 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-17$$wger
000298230 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-17$$wger
000298230 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000298230 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000298230 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000298230 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-17
000298230 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-17
000298230 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-17
000298230 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-17
000298230 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-17
000298230 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000298230 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2024-12-17
000298230 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2024-12-17
000298230 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000298230 980__ $$ajournal
000298230 980__ $$aVDB
000298230 980__ $$aI:(DE-He78)C020-20160331
000298230 980__ $$aUNRESTRICTED